Journal of Diagnostics Concepts & Practice >

2022 , Vol. 21 >Issue 04: 497 - 503

DOI: https://doi.org/10.16150/j.1671-2870.2022.04.013

Original articles

Primary antiphospholipid syndrome complicated with moyamoya syndrome: a case report and literature review

Expand
  • Department of Neurology, Qilu Hospital, Shandong University, Shandong, Jinan 250012, China

Received date: 2022-01-26

  Online published: 2022-11-07

Fold

Abstract

Objective: To analyze the clinical data of a case of primary antiphospholipid syndrome (PAPS) combined with moyamoya syndrome (MMS), and to explore the clinical characteristics of APS combined with MMS. Methods:The clinical data of a patient with PAPS and MMS were collected and analyzed by searching the relevant literatures. Results: The patient was a 23 year old female with 2 pathological pregnancies. The disease started with cerebral infarction. Cerebrovascular imaging showed severe stenosis or occlusion of bilateral internal carotid arteries with collateral vessels formation, which was consistent with MMS findings. Abdominal CT showed splenomegaly. The symptoms were improved after anticoagulation and immunosuppressive therapy. Through literature review at home and abroad, 7 patients with APS complicated with smoky vascular changes with detailed clinical data were found, all of them were female, with an average age of 26.6 years. Their clinical manifestations were heterogeneous, in which limb weakness was a common symptom, with arteriovenous thrombosis, pathological pregnancy and persistent positive antiphospholipid antibody as the main clinical manifestations. A total of 6 patients were followed up in detail, and the symptoms of the 5 patients were improved after anticoagulation and immunosuppressive therapy. One patient died of cerebral hemorrhage. Conclusions: APS is an autoimmune disease involving multiple systems. The case report of APS with MMS is very rare. The anticoagulant or antiplatelet therapy of APS is contradictory to the risk of bleeding in the collateral vessels of MMS, so dual antiplatelet therapy should be carefully selected.

Key words： Antiphospholipid syndrome; Moyamoya syndrome; Pathological pregnancy; Ischemic stroke; Splenomegaly

Cite this article

SONG Luoqing, DAI Tingjun . Primary antiphospholipid syndrome complicated with moyamoya syndrome: a case report and literature review[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(04) : 497 -503 . DOI: 10.16150/j.1671-2870.2022.04.013

References

[1] Gris JC, Brenner B. Antiphospholipid antibodies: neuropsychiatric presentations[J]. Semin Thromb Hemost, 2013, 39(8):935-942.
[2] Mayer M, Cerovec M, Rados M, et al. Antiphospholipid syndrome and central nervous system[J]. Clin Neurol Neurosurg, 2010, 112(7):602-608.
[3] Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives[J]. Lancet Neurol, 2008, 7(11):1056-1066.
[4] 顾宇翔, 毛颖. 烟雾病诊疗的挑战和机遇[J]. 中华神经外科杂志, 2019, 35(7):649-652.
[4] Gu YX, Mao Y. Challenges and opportunities of moyamoya disease diagnosis and treatment[J]. Chin J Neurosurg, 2019, 35(7):649-652.
[5] Wang Z, Fu Z, Wang J, et al. Moyamoya syndrome with antiphospholipid antibodies: a case report and literature review[J]. Lupus, 2014, 23(11):1204-1206.
[6] Booth F, Yanofsky R, Ross IB, et al. Primary antiphospholipid syndrome with moyamoya-like vascular changes[J]. Pediatr Neurosurg, 1999, 31(1):45-48.
[7] Yamashita Y, Kusaga A, Koga Y, et al. Noonan syndrome, moyamoya-like vascular changes, and antiphospholipid syndrome[J]. Pediatr Neurol, 2004, 31(5):364-366.
[8] Shuja-Ud-Din MA, Ahamed SA, Baidas G, et al. Moyamoya syndrome with primary antiphospholipid syndrome[J]. Med Princ Pract, 2006, 15(3):238-241.
[9] 左瑜, 李春, 张淼, 等. 抗磷脂综合征合并烟雾病血管改变一例[J]. 中华风湿病学杂志, 2015, 19(2):125-126.
[9] Zuo Y, Li C, Zhang M, et al. A case of antiphospholipid syndrome with vascular changes in moyamoya disease[J]. Chin J Rheumatol, 2015, 19(2):125-126.
[10] 岳月红, 赵永波, 肖向建, 等. 烟雾病合并甲状腺功能亢进症和抗磷脂综合征:1例报告并文献复习[J]. 国际脑血管病杂志, 2016, 24(2):150-153.
[10] Yue YH, Zhao YB, Xiao XJ, et al. Moyamoya disease complicated with hyperthyroidism and antiphospholipid syndrome:a case report and literature review[J]. Int J Cerebrovasc Dis, 2016, 24(2):150-153.
[11] 王梓, 张磊, 陈吉相, 等. 与抗心磷脂抗体综合征相关的烟雾病1例报道[J]. 卒中与神经疾病, 2016, 23(2):136.
[11] Wang Z, Zhang L, Chen JX, et al. A case report of moyamoya disease associated with anticardiolipin antibody syndrome[J]. Stroke & Nerv Dis, 2016, 23(2):136.
[12] Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS)[J]. J Thromb Haemost, 2006, 4(2):295-306.
[13] Petri M. Epidemiology of the antiphospholipid antibody syndrome[J]. J Autoimmun, 2000, 15(2):145-151.
[14] 石慧, 杨程德. 2019年欧洲抗风湿病联盟成人抗磷脂综合征治疗推荐解读:高风险抗体谱的定义和抗凝方案细化[J]. 中华风湿病学杂志, 2020, 24(2):73-78.
[14] Shi H, Yang CD. Interpretation of 2019 European League Against Rheumatism recommendations for the manage-ment of antiphospholipid syndrome in adults: definition of high-risk antiphospholipid antibodies pro-file and refinement of anticoagulation regimen[J]. Chin J Rheumatol, 2020, 24(2):73-78.
[15] Carmi O, Berla M, Shoenfeld Y, et al. Diagnosis and management of catastrophic antiphospholipid syndrome[J]. xpert Rev Hematol, 2017, 10(4):365-374.
[16] Cohen D, Berger SP, Steup-Beekman GM, et al. Diagnosis and management of the antiphospholipid syndrome[J]. BMJ, 2010, 340:c2541.
[17] Shi H, Teng JL, Sun Y, et al. Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort[J]. Clin Rheumatol, 2017, 36(3):599-608.
[18] Aringer M, Costenbader K, Daikh D, et al. 2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus[J]. Arthritis Rheumatol, 2019, 71(9):1400-1412.
[19] Shiboski CH, Shiboski SC, Seror R, et al. 2016 American college of rheumatology/european league against rheumatism classification criteria for primary Sjögren′s syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheu-matol, 2017, 69(1):35-45.
[20] 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4):242-251.
[20] Rheumatology branch of Chinese Medical Association. 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis[J]. Chin J Int Med, 2018, 57(4):242-251.
[21] slam MA, Alam F, Kamal MA, et al. ‘Non-Criteria’ Neu-rologic Manifestations of Antiphospholipid Syndrome: A Hidden Kingdom to be Discovered[J]. CNS Neurol Disord Drug Targets, 2016, 15(10):1253-1265.
[22] Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients[J]. Arthritis Rheum, 2002, 46(4):1019-1027.
[23] Fujieda Y, Atsumi T, Amengual O, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrom[J]. Lupus, 2012, 21(14):1506-1514.
[24] Kaushik S, Federle MP, Schur PH, et al. Abdominal thrombotic and ischemic manifestations of the antiphospholipid antibody syndrome: CT findings in 42 patients[J]. Radiology, 2001, 218(3):768-771.
[25] Cacciapaglia F, Vadacca M, Coppolino G, et al. Spontaneous splenorenal shunt in a patient with antiphospholipid syndrome: the first case reported[J]. Lupus, 2007, 16(1):56-58.
[26] Manner H, Jung B, Tonassi L, et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine[J]. Am J Med Sci, 2008, 335(5):394-397.
[27] Vassilakopoulos TP, Pangalis GA, Siakantaris MP, et al. Kikuchi's lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome[J]. Rheumatol Int, 2010, 30(7):925-932.
[28] Cikrikcioglu MA, Hursitoglu M, Erkal H, et al. Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity[J]. Pathophysiol Haemost Thromb, 2010, 37(2-4):104-109.
[29] Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome[J]. N Engl J Med, 2009, 360(12):1226-1237.
[30] 烟雾病和烟雾综合征诊断与治疗中国专家共识编写组, 国家卫生计生委脑卒中防治专家委员会缺血性卒中外科专业委员会. 烟雾病和烟雾综合征诊断与治疗中国专家共识(2017)[J]. 中华神经外科杂志, 2017, 33(6):541-547.
[30] Chinese expert consensus compilation group for the diagnosis and treatment of moyamoya disease and moyamoya syndrome, national health and family planning commission stroke prevention and treatment expert committee ischemic stroke surgery professional committee. consensus of Chinese experts on the diagnosis and treatment of moyamoya disease and moyamoya syndrome(2017)[J]. Chin J Neurosurg, 2017, 33(6):541-547.
[31] Sciascia S, Amigo MC, Roccatello D, et al. Diagnosing antiphospholipid syndrome: ‘extra-criteria’ manifestations and technical advances[J]. Nat Rev Rheumatol, 2017, 13(9):548-560.
[32] 刘畅, 赵金霞. 抗磷脂综合征相关血管病变的诊治进展[J]. 中华风湿病学杂志, 2021, 25(4):277-282.
[32] Liu C, Zhao JX. Progress in diagnosis and treatment of antiphospholipid syndrome related vascular diseases[J]. Chin J Rheumatol, 2021, 25(4):277-282.
[33] 赵久良, 李梦涛, 田新平, 等. 血栓性抗磷脂综合征的十个常见问题[J]. 中华内科杂志, 2020, 59(10):820-823.
[33] Zhao JL, Li ML, Tian XP, et al. Top 10 questions that rheumatologists should know about thrombotic antiphospholipid syndrome[J]. Chin J Int Med, 2020, 59(10):820-823.
Options
Outlines

/

〈 〉